Neo Ivy Capital Management Sage Therapeutics, Inc. Transaction History

Neo Ivy Capital Management

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 15, 2023	BUY	$40.65 - $59.54 $211,217 - $309,369	5,196 Added 102.0%	10,290 $483,000
Q4 2022 Mar 24, 2023	BUY	$32.2 - $43.61 $164,026 - $222,149	5,094 New	5,094 $194,000
Q3 2021 Nov 16, 2021	SELL	$40.26 - $57.37 $82,331 - $117,321	-2,045 Closed	0 $0
Q2 2021 Aug 16, 2021	BUY	$54.88 - $79.29 $112,229 - $162,148	2,045 New	2,045 $116,000
Q1 2021 Oct 07, 2021	SELL	$70.65 - $96.76 $101,312 - $138,753	-1,434 Closed	0 $0
Q4 2020 Feb 16, 2021	SELL	$58.41 - $89.06 $167,111 - $254,800	-2,861 Reduced 66.61%	1,434 $124,000
Q3 2020 Nov 17, 2020	BUY	$41.13 - $62.45 $176,653 - $268,222	4,295 New	4,295 $262,000

218

48.2M

854K

195K

Ticker SAGE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 59,422,300
Market Cap $395M
Description
Sage Therapeutics, Inc., a biopharmaceutical company, develops and commercializes medicines to treat central nervous system disorders. Its lead product candidate is ZULRESSO, an intravenous formulation of brexanolone for the treatment of postpartum depression (PPD) in adults. The company's product pipeline also includes zuranolone, a neuroactive...

Get notified when there are updates to the investment portfolio of Neo Ivy Capital Management, based on Form 13F filings with the SEC.

Stay updated on Neo Ivy Capital Management with notifications on news.